National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS 2016-1 with a closing date of October 16, 2015, for receipt of proposals, soon will be available electronically through the NIH Small Business Research Funding Opportunities (http://sbir.nih.gov) Web site and at fedbizopps.gov. The SBIR Phase I, Fast-Track, Direct to Phase II Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site and fedbizopps.gov for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern AND (4) has, including its affiliates, no more than 500 employees. Following are the research topics identified in the NIH/CDC SBIR Contract Solicitation PHS 2016-1: NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CANCER INSTITUTE (NCI): Development of Metabolomics Data Integration Methods and Software; Validation of Mobile Technologies for Clinical Assessment, Monitoring and Intervention; An Electronic Platform for Cognitive Assessment in Cancer Patients; Technologies for Differential Isolation of Exosomes and Oncosomes; Predictive Biomarkers of Adverse Reactions to Radiation Treatment; Molecularly Targeted Radiation Therapy for Cancer Treatment; Signal Amplification to Enable Attomolar Quantitation in Slide-Based or ELISA Biomarker Immunoassays; Identification and Capture of Enriched Tumor Zones with Preservation of Labile Biomarkers from Ultra-Cold Biopsies; Proximity Slide Based Sandwich Immunoassay to Visualize Intramolecular Epitopes of Analytes in Tissue Sections; Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer; Modulating the Microbiome to Improve Efficacy of Cancer Therapeutics; Cell and Animal-Based Models to Advance Cancer Health Disparity Research; Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis; Companion Diagnostics for Cancer Immunotherapies. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Development of Stem Cell-based Assay for High-Throughput Screening of Chemicals of Toxicological Concern; Development of Smart Plate Technology. NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI): Transcatheter Cavopulmonary Bypass Endograft; Active MRI Transseptal Needle; Bioabsorbable Stents for Neonatal Aortic Coarctation; Early Detection and Monitoring of Cardiac Injury Due to Cardiotoxicity. NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA): Development of Novel Compounds to Treat Alcohol Use Disorder. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Precision Genome Engineering for HIV Eradication; High-Throughput Assay Platform for Quantifying Latent HIV Reservoirs; Method for the Detection of Minority Populations of Drug Resistant HIV; Simple, Inexpensive Device to Purify DNA from Sputum for Tuberculosis Testing; Telemonitoring for Infectious Diseases: A Remote System for Assessing Patient Parameters and Specimen Analysis; Innovative Oral Formulations for Anti-Infective Drugs; Vaccines against Pathogens with Small Market Potential. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Development of Primer and Reference Tool to Assess Neonatal Abstinence Syndrome; Therapeutic Cannabidiol Pulmonary Delivery Device (e.g. Nebulizer, Vaporizer or Inhaler); "The Pain Mobile": Remote Pain Management System. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) CENTER FOR GLOBAL HEALTH (CGH): Diagnostic Tools to Support the Elimination and Control of Neglected Tropical Diseases. NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASES (NCEZID): De novo assembly of arthropod genomes of public health importance; Detecting Lower Intestinal Microbiome Disruption and Multidrug Resistant Organisms. NATIONAL CENTER FOR HIV/AIDs, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Serologic measurement of hepatitis B virus cccDNA; Serologic detection and quantification of hepatitis B core antigen. NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Thermostable Dry Powder Live Attenuated Influenza Vaccine for Nasal Delivery. Note: The PHS 2015-2 Omnibus Solicitation of the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Administration for Children and Families for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) GRANT Applications, where investigator-initiated ideas are encouraged, is open and is available at the same Web site noted above with a due dates of September 5, 2015, January 5, 2016, and April 5, 2016.) To understand better the differences between grants and contracts, see LINKURL:https://sbir.nih.gov/apply LINKURL: https://sbir.nih.gov/ LINKDESC: National Institutes of Health Small Business (SBIR/STTR) Research Funding Opportunities. E-mail: sbir@od.nih.gov For general information regarding the NIH/CDC SBIR program, please refer to: Office of Extramural Programs, Office of Extramural Research National Institutes of Health Email: sbir@od.nih.gov Phone: 301-435-2688 Questions regarding this specific contract solicitation should be directed to the 'Primary Point of Contact' and/or 'Secondary Point of Contact' designated in this Notice.
